Purpose: Fifteen cases of lymphocytic hypophysitis due to IgG4-related disease have been reported demonstrating marked improvement with corticosteroid therapy. This is the first case of IgG4-related hypophysitis demonstrating improvement with azathioprine, where corticosteroids were initially tried but ceased due to concern regarding enlargement of the pituitary infiltrate.

Methods: Case description and review of 15 cases reported in the literature. A 40 year old male was diagnosed with IgG-4 related disease based on pituitary and lacrimal gland biopsies associated with raised serum concentration of IgG4. The patient was commenced on prednisolone 30 mg/day, as rapid response to prednisolone treatment has been described in the literature for other cases of IgG4-related hypophysitis. Over the next 3 months, prednisolone treatment resulted in a reduction of serum IgG4 levels, but repeat MRI scan showed an enlarging pituitary mass with new optic nerve compression. Azathioprine 75 mg twice daily was commenced and in the subsequent 3 months, IgG4 levels normalised (0.58 g/L) and MRI scan showed 50% shrinkage of the pituitary mass. After 10 months of azathioprine treatment the MRI showed a normal sized pituitary but persistence of the infraorbital nerve thickening.

Conclusions: Hypophysitis due to IgG4-related disease usually demonstrates prompt response to corticosteroids. This case highlights the need to image promptly after starting treatment to exclude an enlarging pituitary mass despite corticosteroid treatment. Alternative therapy with azathioprine can result in marked improvement. It should be remembered that IgG-4 related hypophysitis is part of a multi-organ disease.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11102-013-0498-9DOI Listing

Publication Analysis

Top Keywords

hypophysitis igg4-related
12
igg4-related disease
12
pituitary mass
12
corticosteroid therapy
8
marked improvement
8
igg4-related hypophysitis
8
prednisolone treatment
8
igg4 levels
8
mri scan
8
enlarging pituitary
8

Similar Publications

Introduction: Endocrine paraneoplastic syndromes (ePNS) are caused by malignant cells that induce hormonal alterations unrelated to the tissue of origin of the neoplasm. The aim of this manuscript is to review the pathophysiology, diagnosis, and treatment of endocrine paraneoplastic syndromes (ePNS).

Areas Covered: We searched the PubMed/Medline, Embase, and Scielo databases, including 96 articles.

View Article and Find Full Text PDF

 Pituitary adenoma is the most common disease that affects the gland and may be classified as functional/nonsecretory tumors. Inflammatory/infective causes may also affect the pituitary gland. The 18F-fluorodeoxyglucose positron emission tomography/computed tomography (F18-FDG PET/CT) may have an incremental value in assessing these lesions and in determining their clinical significance.

View Article and Find Full Text PDF
Article Synopsis
  • - Immune checkpoint inhibitors, like pembrolizumab used in melanoma treatment, can cause rare autoimmune reactions affecting endocrine glands, leading to conditions like hyperthyroidism and hypothyroidism.
  • - A 39-year-old man experienced a sequence of endocrine issues following his pembrolizumab treatment, including thyrotoxicosis, hypothyroidism, and central adrenal insufficiency.
  • - This case highlights the need for careful monitoring of hormonal functions in patients undergoing immunotherapy due to the variability and unusual nature of these endocrine side effects.
View Article and Find Full Text PDF

A 72-year-old man presented with several months of weakness, poor appetite, and depressed moods. Laboratory tests indicated central hypocortisolism, hypothyroidism and hypogonadism, and mild hyperprolactinemia. Imaging indicated a homogenously enhancing solid suprasellar mass inseparable from the hypothalamus and contiguous with a thickened proximal infundibulum.

View Article and Find Full Text PDF
Article Synopsis
  • This systematic review investigates recent cases of hypophysitis—an inflammation of the pituitary gland—in patients who have recovered from COVID-19.
  • Seven cases were studied, mainly involving young adults, with symptoms like headaches and increased thirst, emerging 2-3 weeks after COVID-19 symptoms.
  • The findings showed various imaging results, with some patients receiving glucocorticoid treatment, but long-term follow-up data was limited, highlighting the rarity and unique presentation of COVID-related hypophysitis.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!